» Articles » PMID: 26377051

Self-reported Use of Novel Psychoactive Substances in a US Nationally Representative Survey: Prevalence, Correlates, and a Call for New Survey Methods to Prevent Underreporting

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2015 Sep 18
PMID 26377051
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In recent years, there has been an increase in emergence and use of novel psychoactive substances (NPS) in the US and worldwide. However, there is little published epidemiological survey data estimating the prevalence of use in the US.

Method: Data on self-reported NPS use came from the National Survey of Drug Use and Health (2009-2013), a national representative sample of non-institutionalized individuals in the US. Subjects were asked to provide names of (non-traditional) drugs they used that they were not specifically asked about. We examined lifetime prevalence and sociodemographic correlates of self-reported use of new and uncommon synthetic drugs (NPS) among subjects ages 12-34-years-old.

Results: 1.2% of subjects self-reported any use of the 57 NPS we examined. Use of psychedelic tryptamines (primarily DMT) was most common, followed by psychedelic phenethylamines (e.g., 2C series) and synthetic cannabinoids. Prevalence of self-reported use of NPS increased from 2009 to 2013 and use was most common among males, whites, older subjects, those of lower income, and among those residing in cities. Lifetime use of various other illicit drugs (e.g., LSD, cocaine, ecstasy/MDMA) was highly prevalent among NPS users.

Conclusion: This the first study reporting on use of a variety of NPS in a nationally representative US sample; however, use appears to be underreported as other national data suggest higher rates of NPS (e.g., synthetic cannabinoid) use. Developing more adaptable survey tools and systematically assessing NPS use would allow researchers to ask about hundreds of NPS and improve reporting as new drugs continue to rapidly emerge.

Citing Articles

Examining the association between aggression and suicide attempts among army soldiers.

Krauss A, Greene A, Edwards E, Goodman M Psychol Med. 2024; 1-9.

PMID: 39582394 PMC: 11650178. DOI: 10.1017/S0033291724002460.


Monitoring illicit pentobarbital availability in the United States: A National Drug Early Warning System briefing.

Palamar J, Fitzgerald N, Goldberger B, Cottler L Drug Alcohol Depend. 2024; 263:112402.

PMID: 39173219 PMC: 11384643. DOI: 10.1016/j.drugalcdep.2024.112402.


Methamphetamine and the Synthetic Cathinone 3,4-Methylenedioxypyrovalerone (MDPV) Produce Persistent Effects on Prefrontal and Striatal Microglial Morphology and Neuroimmune Signaling Following Repeated Binge-like Intake in Male and Female Rats.

Nagy E, Overby P, Leyrer-Jackson J, Carfagno V, Acuna A, Olive M Brain Sci. 2024; 14(5).

PMID: 38790414 PMC: 11118022. DOI: 10.3390/brainsci14050435.


Effects of repeated binge intake of the pyrovalerone cathinone derivative 3,4-methylenedioxypyrovalerone on prefrontal cytokine levels in rats - a preliminary study.

Nagy E, Leyrer-Jackson J, Hood L, Acuna A, Olive M Front Behav Neurosci. 2023; 17:1275968.

PMID: 38025384 PMC: 10668493. DOI: 10.3389/fnbeh.2023.1275968.


Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the "God Molecule".

Al-Imam A, Motyka M, Hoffmann B, Magowska A, Michalak M Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375778 PMC: 10302259. DOI: 10.3390/ph16060831.


References
1.
Kelly B, Wells B, Pawson M, Leclair A, Parsons J, Golub S . Novel psychoactive drug use among younger adults involved in US nightlife scenes. Drug Alcohol Rev. 2013; 32(6):588-93. PMC: 3833082. DOI: 10.1111/dar.12058. View

2.
Law R, Schier J, Martin C, Chang A, Wolkin A . Notes from the Field: Increase in Reported Adverse Health Effects Related to Synthetic Cannabinoid Use - United States, January-May 2015. MMWR Morb Mortal Wkly Rep. 2015; 64(22):618-9. PMC: 4584925. View

3.
Helander A, Beck O, Hagerkvist R, Hulten P . Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project. Scand J Clin Lab Invest. 2013; 73(5):400-6. DOI: 10.3109/00365513.2013.793817. View

4.
Forrester M . NBOMe designer drug exposures reported to Texas poison centers. J Addict Dis. 2014; 33(3):196-201. DOI: 10.1080/10550887.2014.950027. View

5.
Vazirian M, Jerry J, James J, Dale R . Bath salts in the emergency department: a survey of emergency clinicians' experience with bath salts-intoxicated patients. J Addict Med. 2014; 9(2):94-8. DOI: 10.1097/ADM.0000000000000094. View